Pharmacological Modulation of Calcium Homeostasis in Familial Dilated Cardiomyopathy: An In Vitro Analysis From an...

Area of Science:

• Cardiovascular Biology
• Genetics
• Stem Cell Biology

Background:

• Inherited cardiomyopathies, like familial dilated cardiomyopathy (DCM), are driven by genetic mutations causing abnormal intracellular calcium (Ca(2+)) sensitivity.
• This initiates pathological remodeling and heart dysfunction.

Purpose of the Study:

• To investigate the impact of β-adrenergic stress on familial DCM using patient-derived cells.
• To evaluate the efficacy of carvedilol and verapamil in mitigating these effects.

Main Methods:

• Utilized human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) from an RBM20 DCM patient.
• Applied β-adrenergic stimulation and assessed Ca(2+) homeostasis, apoptosis (TUNEL assay), and sarcomeric organization.
• Tested pretreatment with β-blocker (carvedilol) and Ca(2+) channel blocker (verapamil).

Main Results:

• β-adrenergic stimulation exacerbated defective Ca(2+) handling, apoptosis, and sarcomeric disarray in familial DCM hiPSC-CMs.
• Pretreatment with carvedilol or verapamil significantly reduced these pathological changes.
• Pharmacological interventions improved Ca(2+) handling and reduced cell death and disorganization.

Conclusions:

• β-adrenergic stress accelerates disease progression in RBM20-deficient familial DCM.
• Carvedilol and verapamil demonstrate potential therapeutic benefits for managing familial DCM.
• Patient-based hiPSC-CM models offer valuable insights for personalized and generalized clinical interventions.